A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
VALNEVA SE operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 179M | 179M | 176M | 157M | 380M | 411M |
| Net Income | -130M | -130M | -13M | -110M | -151M | -87M |
| EPS | $-0.77 | $-0.77 | $-0.09 | $-0.79 | $-1.31 | $-0.89 |
| Free Cash Flow | -65M | -65M | -88M | -236M | -289M | -18M |
| ROIC | -16.3% | -37.4% | 5.6% | -53.3% | -99.3% | -54.6% |
| Gross Margin | 32.2% | 32.2% | 39.6% | 30.3% | 10.2% | 46.0% |
| Debt/Equity | 0.00 | 1.52 | 0.92 | 1.35 | 0.56 | 1.63 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -93M | -93M | 14M | -89M | -119M | -72M |
| Operating Margin | -52.0% | -52.0% | 8.2% | -56.8% | -31.4% | -17.6% |
| ROE | -108.5% | -82.5% | -7.9% | -59.4% | -69.7% | -59.7% |
| Shares Outstanding | 169M | 169M | 153M | 139M | 138M | 105M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 141M | 127M | 411M | 380M | 157M | 176M | 179M | 179M |
| Gross Margin | 58.2% | 50.8% | 46.0% | 10.2% | 30.3% | 39.6% | 32.2% | 32.2% |
| R&D | -43M | -97M | -204M | -110M | -65M | -80M | -97M | -97M |
| SG&A | N/A | N/A | N/A | 269M | N/A | 136M | N/A | N/A |
| EBIT | -908K | -63M | -72M | -119M | -89M | 14M | -93M | -93M |
| Op. Margin | -0.6% | -50.0% | -17.6% | -31.4% | -56.8% | 8.2% | -52.0% | -52.0% |
| Net Income | -2.0M | -74M | -87M | -151M | -110M | -13M | -130M | -130M |
| Net Margin | -1.4% | -58.4% | -21.1% | -39.7% | -70.1% | -7.5% | -72.9% | -72.9% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -0.9% | -60.0% | -54.6% | -99.3% | -53.3% | 5.6% | -37.4% | -16.3% |
| ROE | -1.3% | -61.6% | -59.7% | -69.7% | -59.4% | -7.9% | -82.5% | -108.5% |
| ROA | N/A | -14.3% | -11.7% | -18.6% | -19.1% | -2.5% | -26.3% | -28.9% |
| Cash Flow | ||||||||
| Op. Cash Flow | 6.2M | 158M | 91M | -258M | -220M | -73M | -60M | -60M |
| Free Cash Flow | -5.6M | 136M | -18M | -289M | -236M | -88M | -65M | -65M |
| Owner Earnings | 6.2M | 158M | 91M | -258M | -220M | -73M | -60M | -60M |
| CapEx | 12M | 22M | 109M | 31M | 15M | 15M | 5.0M | 5.0M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 5.0M |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 189.9% | 13.7% | 119.9% | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 247K | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 13M | 25M | 2.3M | 1.9M | 2.3M | 4.0M | 194M | 194M |
| Balance Sheet | ||||||||
| Net Debt | N/A | -9.8M | -81M | -171M | 51M | -1.9M | 58M | -124M |
| Cash & Equiv. | 72M | 235M | 409M | 302M | 137M | 182M | 124M | 124M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | 180M | 183M | 183M |
| Debt/Equity | N/A | 2.53 | 1.63 | 0.56 | 1.35 | 0.92 | 1.52 | 0.00 |
| Interest Coverage | -0.3 | -5.1 | -3.6 | -6.0 | -3.5 | 0.6 | -2.0 | -2.0 |
| Equity | 151M | 89M | 201M | 231M | 139M | 196M | 120M | 120M |
| Total Assets | N/A | 516M | 964M | 654M | 499M | 540M | 452M | 452M |
| Total Liabilities | N/A | 427M | 763M | 423M | 360M | 344M | 331M | 331M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 27M | 25M | 25M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | N/A | 152M | 256M | 155M | 113M | 199M | 146M | 146M |
| Current Assets | N/A | 354M | 691M | 447M | 285M | 323M | 252M | 252M |
| Current Liabilities | N/A | 202M | 435M | 292M | 172M | 124M | 106M | 106M |
| Per Share Data | ||||||||
| EPS | -0.02 | -0.82 | -0.89 | -1.31 | -0.79 | -0.09 | -0.77 | -0.77 |
| Owner EPS | 0.07 | 1.74 | 0.86 | -1.87 | -1.58 | -0.47 | -0.35 | -0.35 |
| Book Value | 1.66 | 0.98 | 1.91 | 1.67 | 1.00 | 1.28 | 0.71 | 0.71 |
| Cash Flow/Share | 0.07 | 1.74 | 0.86 | -1.87 | -1.58 | -0.47 | -0.35 | -0.77 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 90.9M | 91.0M | 105.2M | 138.4M | 138.9M | 153.1M | 169.4M | 169.4M |
| Valuation | ||||||||
| P/E Ratio | -125.1 | -12.7 | -33.1 | -5.2 | -6.6 | -25.8 | -5.5 | -3.4 |
| P/FCF | N/A | 6.9 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 23.6 | N/A | N/A |
| Price/Book | 1.7 | 10.6 | 15.3 | 4.1 | 5.2 | 1.7 | 6.0 | 3.7 |
| Price/Sales | 1.8 | 7.4 | 7.5 | 2.5 | 4.6 | 1.9 | 4.0 | 2.5 |
| FCF Yield | -2.2% | 14.5% | -0.6% | -30.8% | -32.5% | -25.6% | -9.0% | -14.5% |
| Market Cap | 255M | 940M | 3.1B | 939M | 725M | 342M | 718M | 447M |
| Avg. Price | 3.47 | 5.20 | 16.13 | 12.08 | 6.33 | 3.42 | 3.88 | 2.64 |
| Year-End Price | 2.80 | 10.33 | 29.26 | 6.79 | 5.22 | 2.23 | 4.24 | 2.64 |
VALNEVA SE passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 31.7%. At current prices, the estimated annualized return to fair value is +0.1%.
VALNEVA SE (VLA-PA) has a 5-year average return on invested capital (ROIC) of -47.8%. This is below average and may indicate limited pricing power.
VALNEVA SE (VLA-PA) has a market capitalization of $447M. It is classified as a small-cap stock.
VALNEVA SE (VLA-PA) does not currently pay a regular dividend.
VALNEVA SE (VLA-PA) operates in the Biotechnology industry, within the Healthcare sector.
VALNEVA SE (VLA-PA) reported annual revenue of $179 million in its most recent fiscal year, based on SEC EDGAR filings.
VALNEVA SE (VLA-PA) has a net profit margin of -72.9%. The company is currently unprofitable.
VALNEVA SE (VLA-PA) generated $-65 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
VALNEVA SE (VLA-PA) has a debt-to-equity ratio of 1.52. This indicates higher leverage, which may increase financial risk.
VALNEVA SE (VLA-PA) reported earnings per share (EPS) of $-0.77 in its most recent fiscal year.
VALNEVA SE (VLA-PA) has a return on equity (ROE) of -82.5%. A negative ROE may indicate losses or negative equity.
VALNEVA SE (VLA-PA) has a 5-year average gross margin of 31.7%. This indicates decent pricing power.
The Ledger Terminal provides 7 years of financial data for VALNEVA SE (VLA-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
VALNEVA SE (VLA-PA) has a book value per share of $0.71, based on its most recent annual SEC filing.